< 1 minute read
Sep. 18, 2021
M3258: An Orally Available, Selective, and Reversible Inhibitor of LMP7
M3258
sel. reversible cov. immunoproteosome inh. oral efficacy (1 mpk) in xeno., Ph. I in MM from SBDD Mol. Cancer Ther., May 27, 2021 Merck KGaA, Darmstadt, DE
Loading...
